Citius Pharmaceuticals Inc (CTXR) Actualités

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway...

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split PR Newswire CRANFORD, N.J., Nov. 22, 2024...

Form 8-K - Current report

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering PR Newswire CRANFORD, N.J...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering PR Newswire CRANFORD, N.J., Nov. 15...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities